Sarah joins MorphoSys from Qiagen N.V., a leading global provider of sample and assay technologies for molecular diagnostics, academic research, the pharmaceutical industry and applied testing. Qiagen is listed in the German indexes MDAX and TecDAX as well as at the New York Stock Exchange. Sarah has held the position of Director Investor Relations since April 2018 at Qiagen N.V. in Hilden. She joined the Investor Relations Department in October 2015, having started as a scientist at Qiagen in 2009. Sarah has a PhD in Chemistry (Dr. rer. nat.) from the University of Münster, held a Postdoctoral position at the King's College London, Department of Pharmacy, and was awarded a habilitation at the University of Göttingen, Department of Inorganic Chemistry. Sarah had also been appointed to a full professorship for Coordination Chemistry / Bioinorganic Chemistry at the Ludwig-Maximilians-University of Munich in 2009 and has a Master of Business Administration (MBA) from the University of Würzburg in collaboration with the Florida Gulf Coast University, USA and Boston University, USA.
"We are extremely happy that we have gained with Sarah a highly experienced and competent Investor Relations expert with a strong scientific background for this important corporate function in our company. We wish her a good start and every success in her new role at MorphoSys", commented Jens Holstein, Chief Financial Officer of MorphoSys AG.
About MorphoSys:
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology to receive regulatory approval. The Company's most advanced proprietary product candidate, MOR208, has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 330 employees. More information at https://www.morphosys.com.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group. Tremfya(R) is a trademark of Janssen Biotech, Inc.
MorphoSys forward looking statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys's results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys's expectations may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that MorphoSys may fail to obtain regulatory approval for MOR208 and that data from MorphoSys's ongoing clinical research programs may not support registrationor further development of its product candidates due to safety, efficacy or other reasons), MorphoSys's reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys's Registration Statement on Form F-1 and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
For more information, please contact:
MorphoSys AG
Dr. Sarah Fakih
Head of Corporate Communications & IR
Alexandra Goller
Director Corporate Communications & IR
Dr. Julia Neugebauer
Director Corporate Communications & IR
Dr. Verena Kupas
Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com
SOURCE: MorphoSys AG
View source version on accesswire.com:
https://www.accesswire.com/540738/Dr-Sarah-Fakih-joins-MorphoSys-as-Head-of-Corporate-Communications-and-Investor-Relations
